https://www.selleckchem.com/pr....oducts/epz004777.htm
With a median follow-up of 52months, the 5-year local, regional, distant control rate, disease-free, overall, and cancer-specific survival were 78%, 92%, 90%, 42%, 50%, and 76% respectively. Patients with cN2-3 had higher rate of 5-year distant metastasis (24% vs 3%, p=0.001), with detrimental impact on DFS (p=0.03) and OS (p0.02) on multivariable analysis. Grade≥3 late toxicity was reported in 9% of patients (most common grade 3 osteoradionecrosis in 6%). Non-operative management of OSCC resulted in a meaningful rate of locoregio
Like
Comment
Share
